Johnson & Johnson Signs a License Agreement with Pulmatrix to Develop Therapies for Lung Cancer

Shots:

• Pulamtrix to receive $7.2M up front, milestones up to $2M on completion of P-Ib study of RV1162/PUR1800 for patients with COPD, with on-track for year-end 2020 from J&J’s Lung Cancer. Lung Cancer Initiative to get an option to access the portfolio of kinase inhibitor targeted for lung cancer
• Post exercising an option, for RV1162/PUR1800 and portfolio of kinase inhibitors Pulmatrix will receive up to $91M as development and commercial milestones plus royalties
• Pulamtrix’s iSPERSE platform enables the formulation of drugs into small, dense, and dispersible particles for drug delivery and deep penetration into the lungs. In 2020, the company expects for P-II Pulmazole program clinical data

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance